Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chaix ML; AC43 ANRS Resistance Group. Visseaux B, et al. Among authors: bocket l. J Antimicrob Chemother. 2020 Jan 1;75(1):183-193. doi: 10.1093/jac/dkz404. J Antimicrob Chemother. 2020. PMID: 31641777
Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.
Bahr GM, De La Tribonniere X, Darcissac E, Ajana F, Bocket L, Sissoko D, Yazdanpanah Y, Dewulf J, Amiel C, Mouton Y. Bahr GM, et al. Among authors: bocket l. J Antimicrob Chemother. 2003 Jun;51(6):1377-88. doi: 10.1093/jac/dkg244. Epub 2003 Apr 25. J Antimicrob Chemother. 2003. PMID: 12716777 Clinical Trial.
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D; ANRS AC11 Resistance study group. Masquelier B, et al. Among authors: bocket l. Antivir Ther. 2004 Jun;9(3):315-23. Antivir Ther. 2004. PMID: 15259894 Clinical Trial.
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups. Chaix ML, et al. Among authors: bocket l. AIDS. 2009 Mar 27;23(6):717-24. doi: 10.1097/QAD.0b013e328326ca77. AIDS. 2009. PMID: 19279445
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG; EOLE Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2012 Oct;67(10):2487-93. doi: 10.1093/jac/dks226. Epub 2012 Jun 25. J Antimicrob Chemother. 2012. PMID: 22733652
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.
Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, Sayon S, Pakianather S, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG. Lambert-Niclot S, et al. Among authors: bocket l. PLoS One. 2012;7(7):e41390. doi: 10.1371/journal.pone.0041390. Epub 2012 Jul 25. PLoS One. 2012. PMID: 22848481 Free PMC article. Clinical Trial.
Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.
Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group. Tubiana R, et al. Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12. Clin Infect Dis. 2013. PMID: 23766338 Clinical Trial.
Virological failure of patients on maraviroc-based antiretroviral therapy.
Raymond S, Maillard A, Amiel C, Peytavin G, Trabaud MA, Desbois D, Bellecave P, Delaugerre C, Soulie C, Marcelin AG, Descamps D, Izopet J; on behalf the ANRS AC11 Resistance Study Group. Raymond S, et al. J Antimicrob Chemother. 2015;70(6):1858-64. doi: 10.1093/jac/dkv026. Epub 2015 Feb 19. J Antimicrob Chemother. 2015. PMID: 25700719
123 results